<DOC>
	<DOCNO>NCT02015520</DOCNO>
	<brief_summary>The primary purpose study identify appropriate dose study medication .</brief_summary>
	<brief_title>Phase IIB Dose Ranging Study Subjects With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Diagnosis active Rheumatoid Arthritis ( RA ) standard criterion ( American Rheumatism association ( ARA ) [ 1987 ] American College Rheumatology/European League Against Rheumatism ( ACR/EULAR ) [ 2010 ] ) least 16 week prior screen ACR global functional status class 1 3 Documented evidence inadequate response tumor necrosis factor ( TNF ) inhibitor All subject must receive treatment minimum dose 15 mg per week Methotrexate least 12 week stable dose 28 day prior screen . A dose low 10 mg Methotrexate permit 15 mg could reach , due toxicity . In Japan , Korea Taiwan , minimum dose 7.5 mg per week permit . Additional treatment Hydroxychloroquine Chloroquine permit , dose approve treatment RA dose stable least 28 day prior screen Minimum 6 swell 6 tender joint 66/68 joint count screen baseline ( Day 1 ) Elevated Highsensitivity ( h ) CRP and/or ESR Active serious infection History active tuberculosis ( TB ) Elevated liver function test ( LFTs )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>